Developer docs
API playgroundTry for free, no card

Search company profiles

Abionic

Full company profile

uuid0002f6m

Namestring
Abionic
Legal namestring
Abionic SA
Websiteurl
abionic.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Abionic SA is a Swiss medical diagnostics company founded in 2010 as a spin-off from EPFL (École Polytechnique Fédérale de Lausanne), headquartered at the Biopôle Lausanne campus in Epalinges, Switzerland. The company develops and commercializes the abioSCOPE®, a near-patient in vitro diagnostic platform based on proprietary nanofluidic immunoassay technology. The platform reads single-use disposable cartridges, most prominently the IVD CAPSULE PSP, which measures Pancreatic Stone Protein (Pancreatic Stone Protein) to enable early sepsis detection up to 72 hours before clinical recognition, delivering quantitative results in approximately 7 minutes from a single 50 µL drop of whole blood. The company also markets an IVD CAPSULE D-DIMER cartridge and integrates with hospital and laboratory information systems.

Abionic's commercial focus is on acute hospital settings where time-to-diagnosis drives outcomes: Emergency Departments, Intensive Care Units, Burn Units and high-acuity Wards. The technology is CE marked, IVDR certified (July 2022), ISO 13485:2016 certified, and FDA 510(k) cleared (October 2024) for the PSP assay, with pediatric approval added in January 2026. The PSP biomarker is now recognized in the 2026 Surviving Sepsis Campaign International Guidelines. The company has built a clinical evidence base of more than 50 peer-reviewed publications validating PSP performance across multiple care settings.

Abionic generates revenue through a razor/blade model combining capital sales of the abioSCOPE reader with recurring sales of single-use IVD Capsule cartridges. Pricing is not publicly disclosed; sales are conducted via a direct B2B enterprise motion targeting hospital leadership, sepsis coordinators and clinical staff. The company has commercial presence in 14+ countries across Europe, the United States, China and Brazil, and employs 11-50 people. Total disclosed funding since inception is approximately CHF 36.7 million across Series A (2012), Series B (2014) and Series C (2017) rounds. Leadership transitioned in April 2024, with Patrick Pestalozzi replacing founder Nicolas Durand as CEO.

Short descriptiontext

Abionic SA is a Swiss diagnostics company that develops the abioSCOPE® nanofluidic point-of-care platform and the IVD CAPSULE PSP assay for early sepsis detection, selling directly to hospital Emergency Departments, ICUs, Burn Units and Wards across Europe and the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEpalinges, Switzerland
HQ citystring
Epalinges
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point-of-care diagnostics, sepsis detection, nanofluidic immunoassay, in vitro diagnostics, rapid blood testing
Industry1 code
PRIMARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
Product category
In Vitro Diagnostic Medical Devices
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Diagnostic Devices and Consumables
TypeHardware Sales
Description

Abionic generates revenue through the sale of its abioSCOPE diagnostic platform (capital equipment) and associated IVD Capsule consumables (single-use test cartridges). The recurring consumables model provides recurring revenue as hospitals perform tests on patients suspected of sepsis.

abionic.com
2IVD Capsule PSP Test
TypeOne Time License
Description

Sale of IVD Capsule PSP test cartridges for sepsis detection, available for use in critical care and emergency settings. Revenue derived from both direct hospital sales and potentially through distribution partnerships as the company expands into the US market.

abionic.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1abioSCOPE
Description

Near-patient rapid in vitro diagnostic platform using nanofluidic immunoassay technology that delivers lab-quality results within minutes from a single drop of whole blood. The device reads disposable cartridges containing test-specific biosensors.

abionic.com
+1 more record
Core offering1 text field

Abionic develops and commercializes the abioSCOPE® near-patient rapid in vitro diagnostic platform based on proprietary nanofluidic immunoassay technology. The platform reads disposable IVD CAPSULE cartridges from a single drop of whole blood, with its flagship assay IVD CAPSULE PSP measuring Pancreatic Stone Protein to enable early sepsis detection in approximately 7 minutes across hospital Emergency Departments, ICUs, Burn Units, and Wards.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • PSP levels rise up to 72 hours before clinical sepsis recognition
+4 more records
Product overview1 text field

Abionic offers a unified diagnostic ecosystem centered on the abioSCOPE® platform, a near-patient rapid diagnostic system that uses nanofluidic immunoassay technology to deliver lab-quality results within minutes from a single drop of blood. The core assay is the IVD CAPSULE PSP (Pancreatic Stone Protein), which runs exclusively on the abioSCOPE® and enables early sepsis detection up to 72 hours before clinical recognition. Additional test cartridges include the IVD CAPSULE D-DIMER. The platform's disposable cartridges contain test-specific biosensors and support single-cartridge multiplex testing. The system integrates with Hospital Information Systems (HIS) and Laboratory Information Systems (LIS) for seamless clinical workflow integration.

Product and service3 records
1abioSCOPE®
CategoryIn Vitro Diagnostic Platform / Capital Equipment
Description

The abioSCOPE® is a near-patient rapid in vitro diagnostic platform using proprietary nanofluidic immunoassay technology to deliver lab-quality quantitative, semi-quantitative, or qualitative results within minutes from a single 50 µL drop of whole blood. It reads disposable single-use IVD CAPSULE cartridges containing test-specific biosensors and integrates with Hospital Information Systems and Laboratory Information Systems for clinical workflow integration. Intended for hospital Emergency Departments, Intensive Care Units, Burn Units, and Wards performing rapid sepsis screening.

2IVD CAPSULE PSP (Pancreatic Stone Protein)
CategoryDiagnostic Consumable / Test Cartridge
Description

IVD CAPSULE PSP is a single-use disposable diagnostic cartridge that measures Pancreatic Stone Protein (Pancreatic Stone Protein) levels from a drop of blood, running exclusively on the abioSCOPE® platform. Results are delivered in approximately 7 minutes, enabling detection of sepsis up to 72 hours before clinical recognition and discriminating septic patients from those with non-infectious systemic inflammatory response syndrome. FDA 510(k) cleared, IVDR certified for both adults and children, and recognized in the 2026 Surviving Sepsis Campaign International Guidelines as a sepsis risk biomarker.

3IVD CAPSULE D-DIMER
CategoryDiagnostic Consumable / Test Cartridge
Description

IVD CAPSULE D-DIMER is a rapid diagnostic test cartridge for D-Dimer detection, CE marked in 2022 and designed to run on the abioSCOPE® platform for hospital point-of-care use.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFoundationalTypeStrategic or Co-development Partner
Description

Abionic was founded in 2010 as a spin-off from EPFL, Switzerland's premier technical university. The company leverages technology developed at the university for its nanofluidic diagnostic platform. This foundational academic partnership provided the core technology IP for the abioSCOPE platform.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Abionic is headquartered at Biopôle Lausanne, a premier life sciences campus in Switzerland. The company moved to new facilities at Biopôle in 2016. This location provides access to the Swiss medtech ecosystem, talent pool, and collaborative research opportunities.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

T2 Biosystems develops rapid molecular diagnostics for sepsis and other bloodstream infections, directly competing with Abionic in the rapid sepsis diagnostics category at hospital point-of-care.

TypeDirect peer
Description

Cytovale's IntelliSep is a rapid cellular biomarker test for sepsis that delivers results in under 10 minutes from a blood sample, directly competing with Abionic's abioSCOPE PSP test in ED and hospital settings.

TypeEmerging player
Description

Inflammatix is developing host-response based rapid diagnostics for acute infections and sepsis, addressing the same clinical decision point as Abionic's PSP test with a different biomarker approach.

TypeBroad incumbent
Description

bioMérieux is a global IVD leader offering PCT (procalcitonin) and other sepsis biomarkers through its VIDAS and BioFire platforms, representing the entrenched incumbent benchmark that PSP competes against in hospital sepsis workups.

5B·R·A·H·M·S / Thermo Fisher Scientific
TypeBroad incumbent
Description

B·R·A·H·M·S (Thermo Fisher) owns the dominant PCT biomarker for sepsis diagnosis (BRAHMS PCT), which is the most established non-CRP sepsis marker and a direct substitute for Abionic's PSP positioning.

TypeBroad incumbent
Description

Roche Diagnostics offers a broad hospital IVD menu including CRP, PCT, and lactate sepsis markers via cobas platforms, and is the dominant incumbent in hospital central lab diagnostics globally.

7Abbott Point of Care
TypeBroad incumbent
Description

Abbott's i-STAT and rapid POC platforms are installed across thousands of US EDs and ICUs, representing the entrenched POC infrastructure that Abionic's abioSCOPE must displace or co-exist with for sepsis testing.

TypeBroad incumbent
Description

QuidelOrtho offers a broad IVD portfolio including hospital sepsis biomarkers (CRP, PCT) on its Vitros and Sofia platforms, competing for the same hospital budget allocations as Abionic.

TypeEmerging player
Description

EKF Diagnostics develops point-of-care analyzers and rapid biomarker tests for hospital use, including inflammatory markers; a smaller niche player comparable to Abionic in scale and POC focus.

10Axis-Shield (Abbott)
TypeOthers
Description

Axis-Shield (now part of Abbott) developed the original CRP and other biomarker POC tests; relevant as a historical comparator and technology lineage reference for Abionic's POC sepsis positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Abionic

In Vitro Diagnostic Medical Devicesabionic.com

Abionic SA is a Swiss diagnostics company that develops the abioSCOPE® nanofluidic point-of-care platform and the IVD CAPSULE PSP assay for early sepsis detection, selling directly to hospital Emergency Departments, ICUs, Burn Units and Wards across Europe and the United States.

What Abionic does

Abionic SA is a Swiss medical diagnostics company founded in 2010 as a spin-off from EPFL (École Polytechnique Fédérale de Lausanne), headquartered at the Biopôle Lausanne campus in Epalinges, Switzerland. The company develops and commercializes the abioSCOPE®, a near-patient in vitro diagnostic platform based on proprietary nanofluidic immunoassay technology. The platform reads single-use disposable cartridges, most prominently the IVD CAPSULE PSP, which measures Pancreatic Stone Protein (Pancreatic Stone Protein) to enable early sepsis detection up to 72 hours before clinical recognition, delivering quantitative results in approximately 7 minutes from a single 50 µL drop of whole blood. The company also markets an IVD CAPSULE D-DIMER cartridge and integrates with hospital and laboratory information systems.

Abionic's commercial focus is on acute hospital settings where time-to-diagnosis drives outcomes: Emergency Departments, Intensive Care Units, Burn Units and high-acuity Wards. The technology is CE marked, IVDR certified (July 2022), ISO 13485:2016 certified, and FDA 510(k) cleared (October 2024) for the PSP assay, with pediatric approval added in January 2026. The PSP biomarker is now recognized in the 2026 Surviving Sepsis Campaign International Guidelines. The company has built a clinical evidence base of more than 50 peer-reviewed publications validating PSP performance across multiple care settings.

Abionic generates revenue through a razor/blade model combining capital sales of the abioSCOPE reader with recurring sales of single-use IVD Capsule cartridges. Pricing is not publicly disclosed; sales are conducted via a direct B2B enterprise motion targeting hospital leadership, sepsis coordinators and clinical staff. The company has commercial presence in 14+ countries across Europe, the United States, China and Brazil, and employs 11-50 people. Total disclosed funding since inception is approximately CHF 36.7 million across Series A (2012), Series B (2014) and Series C (2017) rounds. Leadership transitioned in April 2024, with Patrick Pestalozzi replacing founder Nicolas Durand as CEO.

Abionic firmographics

Firmographics
Name
Abionic
Legal name
Abionic SA
Website
https://abionic.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
Abionic SA is a Swiss diagnostics company that develops the abioSCOPE® nanofluidic point-of-care platform and the IVD CAPSULE PSP assay for early sepsis detection, selling directly to hospital Emergency Departments, ICUs, Burn Units and Wards across Europe and the United States.
Ownership category
akta.pro rank

Abionic industry classification

Industry
Product category
In Vitro Diagnostic Medical Devices
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Equipment and Supplies Manufacturing (3391)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Point-of-care diagnostics
  • Sepsis detection
  • Nanofluidic immunoassay
  • In vitro diagnostics
  • Rapid blood testing

Where Abionic is headquartered

Location

Headquarters

HQ city
Epalinges
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Abionic business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Diagnostic Devices and Consumables: Abionic generates revenue through the sale of its abioSCOPE diagnostic platform (capital equipment) and associated IVD Capsule consumables (single-use test cartridges). The recurring consumables model provides recurring revenue as hospitals perform tests on patients suspected of sepsis.
  2. IVD Capsule PSP Test: Sale of IVD Capsule PSP test cartridges for sepsis detection, available for use in critical care and emergency settings. Revenue derived from both direct hospital sales and potentially through distribution partnerships as the company expands into the US market.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Abionic product offering

Product offering

Core offering

Abionic develops and commercializes the abioSCOPE® near-patient rapid in vitro diagnostic platform based on proprietary nanofluidic immunoassay technology. The platform reads disposable IVD CAPSULE cartridges from a single drop of whole blood, with its flagship assay IVD CAPSULE PSP measuring Pancreatic Stone Protein to enable early sepsis detection in approximately 7 minutes across hospital Emergency Departments, ICUs, Burn Units, and Wards.

Product overview

Abionic offers a unified diagnostic ecosystem centered on the abioSCOPE® platform, a near-patient rapid diagnostic system that uses nanofluidic immunoassay technology to deliver lab-quality results within minutes from a single drop of blood. The core assay is the IVD CAPSULE PSP (Pancreatic Stone Protein), which runs exclusively on the abioSCOPE® and enables early sepsis detection up to 72 hours before clinical recognition. Additional test cartridges include the IVD CAPSULE D-DIMER. The platform's disposable cartridges contain test-specific biosensors and support single-cartridge multiplex testing. The system integrates with Hospital Information Systems (HIS) and Laboratory Information Systems (LIS) for seamless clinical workflow integration.

Differentiator

Problem solved

Functional benefit

Brands

  • abioSCOPE: Near-patient rapid in vitro diagnostic platform using nanofluidic immunoassay technology that delivers lab-quality results within minutes from a single drop of whole blood. The device reads disposable cartridges containing test-specific biosensors.
  • IVD CAPSULE PSP

Products and services

  • abioSCOPE® The abioSCOPE® is a near-patient rapid in vitro diagnostic platform using proprietary nanofluidic immunoassay technology to deliver lab-quality quantitative, semi-quantitative, or qualitative results within minutes from a single 50 µL drop of whole blood. It reads disposable single-use IVD CAPSULE cartridges containing test-specific biosensors and integrates with Hospital Information Systems and Laboratory Information Systems for clinical workflow integration. Intended for hospital Emergency Departments, Intensive Care Units, Burn Units, and Wards performing rapid sepsis screening.
  • IVD CAPSULE PSP (Pancreatic Stone Protein) IVD CAPSULE PSP is a single-use disposable diagnostic cartridge that measures Pancreatic Stone Protein (Pancreatic Stone Protein) levels from a drop of blood, running exclusively on the abioSCOPE® platform. Results are delivered in approximately 7 minutes, enabling detection of sepsis up to 72 hours before clinical recognition and discriminating septic patients from those with non-infectious systemic inflammatory response syndrome. FDA 510(k) cleared, IVDR certified for both adults and children, and recognized in the 2026 Surviving Sepsis Campaign International Guidelines as a sepsis risk biomarker.
  • IVD CAPSULE D-DIMER IVD CAPSULE D-DIMER is a rapid diagnostic test cartridge for D-Dimer detection, CE marked in 2022 and designed to run on the abioSCOPE® platform for hospital point-of-care use.

Quantifiable outcome

  • PSP levels rise up to 72 hours before clinical sepsis recognition
  • +4 more outcomes

Companies that use Abionic

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Abionic technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature3 records

Abionic partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered foundational and core.

  • EPFL (École Polytechnique Fédérale de Lausanne)foundationalStrategic or Co-development PartnerAbionic was founded in 2010 as a spin-off from EPFL, Switzerland's premier technical university. The company leverages technology developed at the university for its nanofluidic diagnostic platform. This foundational academic partnership provided the core technology IP for the abioSCOPE platform.
  • Biopôle LausannecoreStrategic or Co-development PartnerAbionic is headquartered at Biopôle Lausanne, a premier life sciences campus in Switzerland. The company moved to new facilities at Biopôle in 2016. This location provides access to the Swiss medtech ecosystem, talent pool, and collaborative research opportunities.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Abionic competitors and assessment

Company assessment

Direct peers

  • T2 Biosystems: T2 Biosystems develops rapid molecular diagnostics for sepsis and other bloodstream infections, directly competing with Abionic in the rapid sepsis diagnostics category at hospital point-of-care.
  • Cytovale: Cytovale's IntelliSep is a rapid cellular biomarker test for sepsis that delivers results in under 10 minutes from a blood sample, directly competing with Abionic's abioSCOPE PSP test in ED and hospital settings.

Emerging players

  • Inflammatix: Inflammatix is developing host-response based rapid diagnostics for acute infections and sepsis, addressing the same clinical decision point as Abionic's PSP test with a different biomarker approach.
  • EKF Diagnostics: EKF Diagnostics develops point-of-care analyzers and rapid biomarker tests for hospital use, including inflammatory markers; a smaller niche player comparable to Abionic in scale and POC focus.

Broad incumbents

  • bioMérieux: bioMérieux is a global IVD leader offering PCT (procalcitonin) and other sepsis biomarkers through its VIDAS and BioFire platforms, representing the entrenched incumbent benchmark that PSP competes against in hospital sepsis workups.
  • B·R·A·H·M·S / Thermo Fisher Scientific: B·R·A·H·M·S (Thermo Fisher) owns the dominant PCT biomarker for sepsis diagnosis (BRAHMS PCT), which is the most established non-CRP sepsis marker and a direct substitute for Abionic's PSP positioning.
  • Roche Diagnostics: Roche Diagnostics offers a broad hospital IVD menu including CRP, PCT, and lactate sepsis markers via cobas platforms, and is the dominant incumbent in hospital central lab diagnostics globally.
  • Abbott Point of Care: Abbott's i-STAT and rapid POC platforms are installed across thousands of US EDs and ICUs, representing the entrenched POC infrastructure that Abionic's abioSCOPE must displace or co-exist with for sepsis testing.
  • QuidelOrtho: QuidelOrtho offers a broad IVD portfolio including hospital sepsis biomarkers (CRP, PCT) on its Vitros and Sofia platforms, competing for the same hospital budget allocations as Abionic.

Others

  • Axis-Shield (Abbott): Axis-Shield (now part of Abbott) developed the original CRP and other biomarker POC tests; relevant as a historical comparator and technology lineage reference for Abionic's POC sepsis positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Abionic social profiles

Digital presence

Abionic compliance and trust

Trust signal

Compliance4 records

Abionic financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Abionic leadership team

Management profile

Number of profiles

Profiles8 records

Abionic funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Abionic M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abionic

What does Abionic do?

Abionic develops and commercializes the abioSCOPE® near-patient rapid in vitro diagnostic platform based on proprietary nanofluidic immunoassay technology. The platform reads disposable IVD CAPSULE cartridges from a single drop of whole blood, with its flagship assay IVD CAPSULE PSP measuring Pancreatic Stone Protein to enable early sepsis detection in approximately 7 minutes across hospital Emergency Departments, ICUs, Burn Units, and Wards.

Is Abionic a public or private company?

Abionic is a private company. It is classified as venture growth investor backed and is currently operating.

When was Abionic founded?

Abionic was founded in 2010. It employs 11 to 50 people.

Where is Abionic based?

Abionic is headquartered in Epalinges, Switzerland, in the Europe region.

How does Abionic make money?

Two revenue lines are on record. Diagnostic Devices and Consumables are the primary driver. The others are IVD Capsule PSP Test.

Who are Abionic's main competitors?

Direct peers on record are T2 Biosystems and Cytovale. Emerging players are Inflammatix and EKF Diagnostics. Broad incumbents are bioMérieux, B·R·A·H·M·S / Thermo Fisher Scientific, Roche Diagnostics, Abbott Point of Care and QuidelOrtho. Axis-Shield (Abbott) is listed as an others.

Does Abionic have an API?

No public API is recorded for Abionic.

What industry is Abionic in?

Abionic's product category is In Vitro Diagnostic Medical Devices. Its primary akta.pro industry code is HLAHAAAN, Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Market Research & Business IntelligencePancreatic Stone Protein Testing Industry: Market Insights 2036Future Market Insights published a market analysis projecting the global pancreatic stone protein (PSP) testing market to grow from USD 2.30 billion in 2026 to USD 2.89 billion by 2036 at a 2.3% CAGR, underpinned by FDA regulatory clearance of the first PSP-based diagnostic platform. Abionic received 510(k) clearance from the US FDA in October 2024 for its IVD Capsule PSP test on the nanofluidic abioSCOPE platform, enabling US market entry for PSP-based sepsis diagnostics, and followed with pediatric approval in January 2026 extending IVDR-compliant coverage from adults to children. The FDA clearance is identified as the most significant inflection point for PSP biomarker adoption since its initial clinical adoption in European ICUs.Business Wire BlogFDA Clears Abionic’s IVD CAPSULE PSP for the Early Detection of SepsisAbionic's IVD CAPSULE PSP test received FDA 510(k) clearance for early sepsis detection. The test measures pancreatic stone protein, a biomarker that can detect sepsis 24-48 hours earlier than current standards. The clearance enables deployment across the U.S. market.Swiss-MedtechDer Swiss Medtech Award 2023 geht an AbionicAbionic was awarded the Swiss Medtech Award 2023 at the Swiss Medtech Day in Bern for its abioSCOPE rapid diagnostic platform. The technology enables point-of-care testing for biomarkers like those indicating sepsis in just five minutes, a capability the jury highlighted as potentially life-saving. The award carries a value of CHF 75,000 and recognizes the company's innovation since its founding in 2010.startupticker.chThe Swiss Medtech Award 2023 goes to AbionicLausanne-based medical technology company Abionic received the Swiss Medtech Award 2023, worth CHF 75,000, at an event attended by approximately 800 industry representatives. The award recognizes Abionic's abioSCOPE platform, a rapid diagnostic test capable of detecting biomarkers for conditions like sepsis in five minutes using nanotechnology. Jury members highlighted the technology's potential to revolutionize in-vitro diagnostics and save lives through faster clinical decision-making.startupticker.chAbionic receives IVDR certification for its ultra-rapid Sepsis testAbionic's Pancreatic Stone Protein (PSP) test on the abioSCOPE received IVDR certification from BSI, allowing sale in the EU. The test detects sepsis up to 72 hours early in 5 minutes, and clinical trials for FDA 510(k) clearance are underway.startupticker.chAbionic launches new tool for faster triage of Covid19 patientsAbionic launched a CE-marked cSOFA score device that assesses Covid-19 severity from a 50-µl blood drop in five minutes. The tool uses the validated biomarker PSP to triage patients, potentially freeing ICU capacity. The company suggests the score could apply to other illnesses like flu and sepsis.Silicon Republic10 awesome start-ups from Lausanne to watchTen Lausanne-based start-ups are profiled, including Abionic, Bestmile, and MindMaze, with details on their products and funding. Abionic raised 25.8m Swiss francs, MindMaze raised $110m, and Sophia Genetics raised $63m. The list highlights medtech, mobility, and fintech innovations from EPFL spin-offs.Le TempsCinq des six PME sélectionnées pour le Prix SVC sont vaudoisesSix finalists of the 2018 Prix SVC Suisse romande were announced, with most from Vaud. The jury selected companies like Abionic, Beqom, and Flyability, and winners will be named on November 8 at EPFL's SwissTech Convention Center.startupticker.chFirst IPO Day in Lausanne on the horizonThe first IPO Day in Lausanne will be held on 13 June at Gotham, where nine selected Swiss tech companies will pitch to 100-150 participants. The companies include Abionic, AMAL Therapeutics, AMYRA, CAScination, Distalmotion, Nanolive, Neeo, Nexthink, NetGuardians, and SWISSto12, with details on their products and funding.